• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4643727)   Today's Articles (4038)   Subscriber (50651)
For: Tolcher AW, Eckhardt SG, Kuhn J, Hammond L, Weiss G, Rizzo J, Aylesworth C, Hidalgo M, Patnaik A, Schwartz G, Felton S, Campbell E, Rowinsky EK. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. J Clin Oncol 2001;19:2937-47. [PMID: 11387367 DOI: 10.1200/jco.2001.19.11.2937] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
Number Cited by Other Article(s)
1
Gordon MS, Shapiro GI, Sarantopoulos J, Juric D, Lu B, Zarotiadou A, Connarn JN, Le Bruchec Y, Dumitru CD, Harvey RD. Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors. Front Oncol 2022;11:786120. [PMID: 35070991 PMCID: PMC8779022 DOI: 10.3389/fonc.2021.786120] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2021] [Accepted: 11/15/2021] [Indexed: 12/14/2022]  Open
2
Mohan CD, Rangappa S, Nayak SC, Jadimurthy R, Wang L, Sethi G, Garg M, Rangappa KS. Bacteria as a treasure house of secondary metabolites with anticancer potential. Semin Cancer Biol 2021;86:998-1013. [PMID: 33979675 DOI: 10.1016/j.semcancer.2021.05.006] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 05/03/2021] [Accepted: 05/03/2021] [Indexed: 12/27/2022]
3
Hevener K, Verstak TA, Lutat KE, Riggsbee DL, Mooney JW. Recent developments in topoisomerase-targeted cancer chemotherapy. Acta Pharm Sin B 2018;8:844-861. [PMID: 30505655 PMCID: PMC6251812 DOI: 10.1016/j.apsb.2018.07.008] [Citation(s) in RCA: 137] [Impact Index Per Article: 22.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2018] [Revised: 07/18/2018] [Accepted: 07/18/2018] [Indexed: 12/17/2022]  Open
4
Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment. Mar Drugs 2018;16:md16070246. [PMID: 30041477 PMCID: PMC6071085 DOI: 10.3390/md16070246] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2018] [Revised: 06/15/2018] [Accepted: 07/18/2018] [Indexed: 12/20/2022]  Open
5
Sherer C, Snape TJ. Heterocyclic scaffolds as promising anticancer agents against tumours of the central nervous system: Exploring the scope of indole and carbazole derivatives. Eur J Med Chem 2015;97:552-60. [DOI: 10.1016/j.ejmech.2014.11.007] [Citation(s) in RCA: 87] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2014] [Revised: 10/30/2014] [Accepted: 11/03/2014] [Indexed: 02/05/2023]
6
Bharate SB, Sawant SD, Singh PP, Vishwakarma RA. Kinase inhibitors of marine origin. Chem Rev 2013;113:6761-815. [PMID: 23679846 DOI: 10.1021/cr300410v] [Citation(s) in RCA: 89] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
7
Schwandt A, Mekhail T, Halmos B, O'Brien T, Ma PC, Fu P, Ivy P, Dowlati A. Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer. J Thorac Oncol 2012;7:751-4. [PMID: 22425925 PMCID: PMC3310884 DOI: 10.1097/jto.0b013e31824abca2] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
8
Advani RH, Hurwitz HI, Gordon MS, Ebbinghaus SW, Mendelson DS, Wakelee HA, Hoch U, Silverman JA, Havrilla NA, Berman CJ, Fox JA, Allen RS, Adelman DC. Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules. Clin Cancer Res 2010;16:2167-75. [DOI: 10.1158/1078-0432.ccr-09-2236] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
9
Nock CJ, Brell JM, Bokar JA, Cooney MM, Cooper B, Gibbons J, Krishnamurthi S, Manda S, Savvides P, Remick SC, Ivy P, Dowlati A. A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors. Invest New Drugs 2009;29:126-30. [PMID: 19774342 DOI: 10.1007/s10637-009-9322-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2009] [Accepted: 09/02/2009] [Indexed: 10/20/2022]
10
Borthakur G, Alvarado Y, Ravandi-Kashani F, Cortes J, Estrov Z, Faderl S, Ivy P, Bueso-Ramos C, Nebiyou Bekele B, Giles F. Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer 2008;113:360-6. [PMID: 18473351 DOI: 10.1002/cncr.23559] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
11
Langevin AM, Bernstein M, Kuhn JG, Blaney SM, Ivy P, Sun J, Chen Z, Adamson PC. A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 2008;50:577-80. [PMID: 17610262 DOI: 10.1002/pbc.21274] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
12
Hartmann JT. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines. Anticancer Drugs 2007;18:245-54. [PMID: 17264755 DOI: 10.1097/cad.0b013e3280124e41] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
13
Kasper B, Gil T, D'Hondt V, Gebhart M, Awada A. Novel treatment strategies for soft tissue sarcoma. Crit Rev Oncol Hematol 2006;62:9-15. [PMID: 17141519 DOI: 10.1016/j.critrevonc.2006.11.008] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2006] [Accepted: 11/15/2006] [Indexed: 11/21/2022]  Open
14
Burstein HJ, Overmoyer B, Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Ivy P, Winer EP. Rebeccamycin analog for refractory breast cancer: A randomized phase II trial of dosing schedules. Invest New Drugs 2006;25:161-4. [PMID: 16969707 DOI: 10.1007/s10637-006-9007-6] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2006] [Accepted: 08/09/2006] [Indexed: 11/25/2022]
15
Dowlati A, Chapman R, Subbiah S, Fu P, Ness A, Cortas T, Patrick L, Reynolds S, Xu N, Levitan N, Ivy P, Remick SC. Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer. Invest New Drugs 2006;23:563-7. [PMID: 16034518 DOI: 10.1007/s10637-005-0754-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
16
Ricart AD, Hammond LA, Kuhn JG, Takimoto CH, Goetz A, Forouzesh B, Forero L, Ochoa-Bayona JL, Berg K, Tolcher AW, Rowinsky EK. Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patients with Advanced Solid Tumors. Clin Cancer Res 2005;11:8728-36. [PMID: 16361560 DOI: 10.1158/1078-0432.ccr-05-1572] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
17
Lee DP, Skolnik JM, Adamson PC. Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct Efficiency. J Clin Oncol 2005;23:8431-41. [PMID: 16293874 DOI: 10.1200/jco.2005.02.1568] [Citation(s) in RCA: 103] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
18
Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins MJ, Von Hoff DD. Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies. J Clin Oncol 2005;23:7785-93. [PMID: 16258082 DOI: 10.1200/jco.2004.00.6148] [Citation(s) in RCA: 206] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]  Open
19
Hartmann JT, Patel S. New drug developments for patients with metastatic soft tissue sarcoma. Curr Oncol Rep 2005;7:300-6. [PMID: 15946590 DOI: 10.1007/s11912-005-0054-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
20
Hartmann JT, Patel S. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs 2005;65:167-78. [PMID: 15631540 DOI: 10.2165/00003495-200565020-00002] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
21
Denny WA. Emerging DNA topoisomerase inhibitors as anticancer drugs. Expert Opin Emerg Drugs 2005. [DOI: 10.1517/14728214.9.1.105] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
22
Al-awar RS, Ray JE, Hecker KA, Huang J, Waid PP, Shih C, Brooks HB, Spencer CD, Watkins SA, Patel BR, Stamm NB, Ogg CA, Schultz RM, Considine EL, Faul MM, Sullivan KA, Kolis SP, Grutsch JL, Joseph S. 1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett 2005;14:3217-20. [PMID: 15149678 DOI: 10.1016/j.bmcl.2004.03.105] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2004] [Accepted: 03/31/2004] [Indexed: 11/18/2022]
23
Hussain M, Vaishampayan U, Heilbrun LK, Jain V, LoRusso PM, Ivy P, Flaherty L. A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer. Invest New Drugs 2004;21:465-71. [PMID: 14586215 DOI: 10.1023/a:1026259503954] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
24
Synthesis of indolo[2,3-a]carbazole glycoside analogs of rebeccamycin: inhibitors of cyclin D1-CDK4. Tetrahedron Lett 2004. [DOI: 10.1016/j.tetlet.2003.10.184] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
25
Moreau P, Gaillard N, Marminon C, Anizon F, Dias N, Baldeyrou B, Bailly C, Pierré A, Hickman J, Pfeiffer B, Renard P, Prudhomme M. Semi-synthesis, topoisomerase I and kinases inhibitory properties, and antiproliferative activities of new rebeccamycin derivatives. Bioorg Med Chem 2003;11:4871-9. [PMID: 14604648 DOI: 10.1016/j.bmc.2003.09.014] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
26
Langevin AM, Weitman SD, Kuhn JG, Weintraub ST, Baruchel S, Furman W, Bernstein M, Blaney S, Vietti T. Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol 2003;25:526-33. [PMID: 12847318 DOI: 10.1097/00043426-200307000-00006] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
27
Facompré M, Carrasco C, Vezin H, Chisholm JD, Yoburn JC, Van Vranken DL, Bailly C. Indolocarbazole glycosides in inactive conformations. Chembiochem 2003;4:386-95. [PMID: 12740810 DOI: 10.1002/cbic.200200478] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
28
Goel S, Wadler S, Hoffman A, Volterra F, Baker C, Nazario E, Ivy P, Silverman A, Mani S. A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer. Invest New Drugs 2003;21:103-7. [PMID: 12795535 DOI: 10.1023/a:1022980613420] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA